Eligibility Criteria:

-Patients must have been assigned to S1400F

-Patients must have progressed during or after prior platinum-based chemotherapy. For patients whose only prior platinum-based chemotherapy regimen was for Stage I-III disease (i.e. patient has not received any platinum-based chemotherapy for Stage IV or recurrent disease), disease progression on platinum-based chemotherapy must have occurred within one year from the last date that patient received that therapy.

Patients must also have experienced disease progression during or after anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment. Prior PD-1/PD-L1 combination therapy is not permitted.
-Prior exposure to CTLA-4 inhibitors (ipilimumab and tremelimumab) is not permitted.
-Patients must not have any history of primary immunodeficiency.
-Patients must have Zubrod performance status 0-1.

***For patients that have progressed/relapse (section 14.4) and are going to continue receiving treatment they must sign an additional optional progression consent.

Substudy G eligibility:
-Patients must be assigned to this substudy. Biomarker eligibility defined as Homologous Recombination Repair Deficiency positive.
-Patients must not have had prior exposure to any agent with a PARP inhibitor
-Patients must have achieved stable disease or a partial or complete response at their first disease assessment after initiating first-line platinum-based chemo.
-Patients whose biomarker profiling results indicate the presence of an EGFR mutation or EML4/ALK fusion are not eligible.
-Patients must have progressed following the most recent line of therapy.
-Patients must have recovered from side effects of prior therapy and surgery.
-Patient must have measurable disease.
-Patient must not have untreated CNS disease.
-ECOG PS must be 0-1

-Patients must have pathologically proven squamous cell carcinoma (SCCA) cancer of the lung confirmed by tumor biopsy and/or fine-needle aspiration. Disease must be Stage IV SCCA or recurrent. The primary diagnosis of SCCA should be established using the current WHO/IASLC-classification of Thoracic Malignancies. Mixed histologies are not allowed.
-To be eligible for screening at progression, patients must have received at least one line of systemic therapy for any stage of disease (Stages I-IV). At least one of these lines of therapy must have been a platinum-based chemotherapy regimen. Patients must have progressed following the most recent line of therapy. For patients whose prior systemic therapy was for Stage I-III disease only (i.e. patient has not received any treatment for Stage IV disease), disease progression on platinum-based chemotherapy must have occurred within one year from the last date that patient received that therapy. 
-To be eligible for pre-screening, current treatment must be for Stage IV disease and patient must have received at least one dose of the current regimen. Patients must have previously received or currently be receiving a platinum-based chemotherapy regimen. Patients on first-line platinum-based treatment are eligible upon receiving Cycle 1, Day 1 infusion.
-Patients must not have a known EGFR mutation or ALK fusion.
-Patients must have Zubrod performance status 0-1

Substudy K eligibility:
- Patients must be assigned to this substudy.
-Patients must have pathologically proven squamous cell carcinoma of the lung
-Patients must not have peripheral edema > Grade 1, or peripheral neuropathy > Grade 1 at the time of sub-study registration.
-Patients must not have received prior treatment with c-Met pathway inhibitors.
-Patients with extensive metastatic liver disease will not be eligible.

*MCRC is not a selected institution for the repeat biopsy substudies.*

-Patients must have histologically or cytologically confirmed Stage IV or recurrent non-small cell lung cancer (NSCLC).
-Patients must have documented presence of an EGFR exon 19 deletion or exon 21 (L858R) substitution mutation. T790M mutation or other molecular abnormality will be allowed as long as it accompanies one of these mutations. 
-Patients must have tissue available and must agree to submission of tissue and blood 
-Patients must not have received any prior systemic anticancer therapy for advanced or metastatic disease including chemotherapy or EGFR tyrosine kinase inhibitor therapy (including gefitinib, erlotinib, afatinib, or any experimental EGFR TKI agents).
-Prior chemotherapy for non-metastatic disease (i.e. adjuvant therapy or concurrent chemo-radiotherapy) is allowed as long as >12 months has passed since completion of therapy. Adjuvant EGFR-directed therapy is not allowed. Local therapy (i.e. palliative radiotherapy) is allowed as long as a period of 7 days has passed since the last dose was received and the patient has recovered from any associated toxicity at the time of registration.
-Patients may have measurable or non-measurable disease. Laboratory parameters are not acceptable as the only evidence of disease. 
-Patient must not have symptomatic brain metastases or evidence of leptomeningeal carcinomatosis. Patients with asymptomatic brain metastases are eligible if off of steroids for at least 7 days prior to registration without development of symptoms. 
-Patients must not have significant gastrointestinal disorders with diarrhea as a major symptom (e.g. Crohn’s disease, malabsorption, etc).
-Patients must not have had major surgery within 28 days prior to registration or be scheduled for surgery during the projected course of protocol treatment.
-Patients must have Zubrod PS 0 - 2

*Credentialing required. Please check your site's credentialing status.*
CURRENT SITES CREDENTIALED:
Genesys Hurley, Hurley, St. John, Macomb, Sparrow, St. Alphonsus, Allegiance, Saginaw, Lehigh Valley 

-Patients must have completely resected melanoma of cutaneous origin or of unknown primary in order to be eligible for this study. Patients must be classified as Stage IIIA (N2a), IIIB, IIIC, or Stage IV melanoma. Patients with melanoma of mucosal or other non-cutaneous origin are eligible. Patients with melanoma of ocular origin are not eligible. Patients with a history of brain metastases are ineligible.
-Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site.
-Patients with multiple regional nodal basin involvement are eligible. Gross or microscopic extracapsular nodal extension is permitted.
-For all patients, all disease must have been resected with negative pathological margins and no clinical, radiologic, or pathological evidence of any incompletely resected melanoma. Patients must be registered within 98 days of the last surgery performed to render the patient free of disease.
-Patients may have received prior radiation therapy, including after the surgical resection. All adverse events associated with prior surgery and radiation therapy must have resolved to less than or equal to Grade 1 prior to registration.
-Patients must not have had prior immunotherapy.
-Patients must not have had previous treatment with ipilimumab
-Zubrod PS must be 0-1.